Detection of Circulating Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 in Non-small Cell Lung Cancer Using Luminex Multiplex Technology

Overview

Journal Oncol Lett

Specialty Oncology

Date 2014 Jan 8

PMID 24396477

Citations 8

Authors

Ye Zhang

Jian-Zhong Wu

Jun-Ying Zhang

Jing Xue

Rong Ma

Hai-Xia Cao

Ji-Feng Feng

Affiliations

Soon will be listed here.

Abstract

It has been previously reported that vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 are important for the occurrence and development of non-small cell lung cancer (NSCLC). The present study was designed to detect the serum levels of VEGF and MMP-9 in NSCLC, and to explore their diagnostic and prognostic values. A total of 543 cases were involved, of which 332 were NSCLC (272 cases in the pretreatment group and 60 cases in the postoperative group), 91 were patients with benign lung diseases and 120 were healthy controls. The serum levels of VEGF and MMP-9 were determined by Luminex multiplex technology. The serum levels of VEGF and MMP-9 were found to be significantly higher in the pretreatment group than those in the patients with benign lung diseases and healthy controls (VEGF, P<0.0001; MMP-9, P<0.0001). Compared with the pretreatment group, the serum levels of VEGF and MMP-9 in the postoperative group were significantly decreased (VEGF, P=0.005; MMP-9, P=0.002), and the levels of VEGF and MMP-9 in the pretreatment group of patients with stages III and IV were higher than those with stages I and II (VEGF, P<0.0001; MMP-9, P=0.021). In addition, the levels of VEGF and MMP-9 were found to closely correlate with lymph node metastasis (VEGF, P<0.0001; MMP-9, P<0.0001) in the pretreatment group, while being independent of other clinicopathological parameters (P>0.05). Furthermore, a positive correlation was observed between the serum levels of VEGF and MMP-9 (r=0.159; P=0.009). A receiver operating characteristic curve analysis showed that the diagnostic value of MMP-9 was higher than that of VEGF in the pretreatment group. The log-rank test indicated that the inoperable NSCLC patients with low levels of VEGF exhibited a significantly longer overall survival time than those with high VEGF levels (P<0.0001). Additionally, the serum levels of VEGF and lymph node metastasis were identified as independent prognostic factors of the inoperable NSCLC patients in a multivariate Cox regression analysis (P<0.05). These results indicated that VEGF and MMP-9 may be potential biomarkers for the diagnosis and prognosis of NSCLC.

Citing Articles

Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy.

Tirpe A, Gulei D, Tirpe G, Nutu A, Irimie A, Campomenosi P Int J Mol Sci. 2020; 21(21).

PMID: 33121202 PMC: 7663714. DOI: 10.3390/ijms21218002.

Emphysema phenotypes and lung cancer risk.

Gonzalez J, Henschke C, Yankelevitz D, Seijo L, Reeves A, Yip R PLoS One. 2019; 14(7):e0219187.

PMID: 31344121 PMC: 6657833. DOI: 10.1371/journal.pone.0219187.

Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis.

Blanco-Prieto S, Barcia-Castro L, Paez de la Cadena M, Rodriguez-Berrocal F, Vazquez-Iglesias L, Botana-Rial M BMC Cancer. 2017; 17(1):823.

PMID: 29207990 PMC: 5718060. DOI: 10.1186/s12885-017-3842-z.

Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer.

Zang J, Hu Y, Xu X, Ni J, Yan D, Liu S Onco Targets Ther. 2017; 10:409-415.

PMID: 28176920 PMC: 5261848. DOI: 10.2147/OTT.S124124.

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units.

Blanco-Prieto S, De Chiara L, Rodriguez-Girondo M, Vazquez-Iglesias L, Rodriguez-Berrocal F, Fernandez-Villar A Sci Rep. 2017; 7:41151.

PMID: 28117344 PMC: 5259733. DOI: 10.1038/srep41151.

References

Zhao P, Dai M, Chen W, Li N . Cancer trends in China. Jpn J Clin Oncol. 2010; 40(4):281-5. DOI: 10.1093/jjco/hyp187. View

Muramatsu M, Yamamoto S, Osawa T, Shibuya M . Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 2010; 70(20):8211-21. DOI: 10.1158/0008-5472.CAN-10-0202. View

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

Jumper C, Cobos E, Lox C . Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004; 98(2):173-7. DOI: 10.1016/j.rmed.2003.08.014. View

Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E . Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest. 2006; 24(6):576-80. DOI: 10.1080/07357900600894781. View

Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G . Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol. 2002; 13(10):1550-7. DOI: 10.1093/annonc/mdf270. View

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

Chakra M, Pujol J, Lamy P, Bozonnat M, Quantin X, Jacot W . Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol. 2008; 3(10):1119-26. DOI: 10.1097/JTO.0b013e318187464e. View

Katsabeki-Katsafli A, Kerenidi T, Kostikas K, Dalaveris E, Kiropoulos T, Gogou E . Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer. 2008; 60(2):271-6. DOI: 10.1016/j.lungcan.2007.10.006. View

10.

Martins S, Takagaki T, Silva A, Gallo C, Silva F, Capelozzi V . Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer. 2008; 64(1):105-9. DOI: 10.1016/j.lungcan.2008.07.017. View

11.

Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H . Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 2005; 183(1):29-42. DOI: 10.1007/s00408-004-2521-4. View

12.

Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H . MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002; 2(4):289-300. DOI: 10.1016/s1535-6108(02)00153-8. View

13.

Farhat F, Tfayli A, Fakhruddin N, Mahfouz R, Otrock Z, Alameddine R . Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 2012; 84(2):149-60. DOI: 10.1016/j.critrevonc.2012.02.012. View

14.

Bremnes R, Camps C, Sirera R . Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2005; 51(2):143-58. DOI: 10.1016/j.lungcan.2005.09.005. View

15.

Fujise N, Nanashim A, Taniguchi Y, Matsuo S, Hatano K, Matsumoto Y . Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 2000; 27(1):19-26. DOI: 10.1016/s0169-5002(99)00088-4. View

16.

Jin Y, Li J, Tang L, Chen J, Feng Z, Liu Y . Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas. Asian Pac J Cancer Prev. 2011; 12(6):1473-6. View

17.

Zhang Y, Yu L, Xia N . Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med. 2012; 5(3):239-42. DOI: 10.1016/S1995-7645(12)60032-7. View

18.

Tamura M, Oda M, Matsumoto I, Tsunezuka Y, Kawakami K, Ohta Y . The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol. 2004; 11(10):928-33. DOI: 10.1245/ASO.2004.01.013. View

19.

Cox G, Jones J, OByrne K . Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000; 6(6):2349-55. View

20.

Hawinkels L, Zuidwijk K, Verspaget H, de Jonge-Muller E, van Duijn W, Ferreira V . VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 2008; 44(13):1904-13. DOI: 10.1016/j.ejca.2008.06.031. View